skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer

Review

(4026) Views  (764) Full article downloads

Authors: Erin M Bertino, Bhuvaneswari Ramaswamy

Published Date May 2010 Volume 2010:2 Pages 13 - 23
DOI: http://dx.doi.org/10.2147/BCTT.S5430

Erin M Bertino, Bhuvaneswari Ramaswamy

Department of Internal Medicine, Division of Hematology-Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA

Abstract: Advanced breast cancer represents a therapeutic challenge for oncologists. Chemotherapy with anthracyclines and taxanes has improved survival in this setting, but resistant and refractory disease is common. Ixabepilone, an epothilone, is a recently approved chemotherapeutic agent, both as a single agent and in combination with capecitabine, with efficacy in patients with resistant advanced disease. In this review, the distinctive properties of this drug are discussed, as well as the clinical evidence of efficacy. Ongoing clinical trials are exploring the role of ixabepilone in several clinical settings: neoadjuvant, adjuvant, and novel combinations.

Keywords: chemotherapy, solid tumor, metastatic disease, neoadjuvant chemotherapy






 

Other articles by Dr Bhuvaneswari Ramaswamy



Readers of this article also read:

New approaches in the management of advanced breast cancer – role of combination treatment with liposomal doxorubicin
Progress in the development of a therapeutic vaccine for breast cancer
Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review
Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal
Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
Potential clinical applications of halichondrins in breast cancer and other neoplasms
A triple negative breast cancer: what it is not!
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University